PRQR
ProQR Therapeutics N.V.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.27
P/S
10.39
EV/EBITDA
-2.15
DCF Value
$-44.84
FCF Yield
-32.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.8%
Operating Margin
-273.0%
Net Margin
-264.9%
ROE
-65.1%
ROA
-37.4%
ROIC
-51.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4.6M | $-8.8M | $-0.09 |
| FY 2025 | $15.3M | $-40.5M | $-0.38 |
| Q3 2025 | $2.9M | $-11.0M | $-0.10 |
| Q2 2025 | $3.8M | $-12.2M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
NL
Exchange
NASDAQ
Beta
0.09
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.